Pacira BioSciences, Inc. $PCRX Shares Sold by Bridge City Capital LLC

Bridge City Capital LLC lessened its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 8.3% in the fourth quarter, HoldingsChannel reports. The fund owned 285,493 shares of the company’s stock after selling 25,951 shares during the period. Pacira BioSciences makes up about 2.2% of Bridge City Capital LLC’s portfolio, making the stock its 5th largest holding. Bridge City Capital LLC’s holdings in Pacira BioSciences were worth $7,389,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Kestra Advisory Services LLC acquired a new position in Pacira BioSciences during the 4th quarter worth $48,000. Rafferty Asset Management LLC acquired a new position in Pacira BioSciences during the 4th quarter worth $240,000. First Trust Advisors LP boosted its position in Pacira BioSciences by 1,838.9% during the 4th quarter. First Trust Advisors LP now owns 188,889 shares of the company’s stock worth $4,888,000 after acquiring an additional 179,147 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Pacira BioSciences by 7.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 676,352 shares of the company’s stock worth $17,504,000 after acquiring an additional 49,079 shares during the period. Finally, Wells Fargo & Company MN boosted its position in Pacira BioSciences by 41.2% during the 4th quarter. Wells Fargo & Company MN now owns 52,486 shares of the company’s stock worth $1,358,000 after acquiring an additional 15,306 shares during the period. Institutional investors and hedge funds own 99.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on PCRX shares. Wall Street Zen lowered Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Royal Bank Of Canada boosted their price target on Pacira BioSciences from $22.00 to $24.00 and gave the stock a “sector perform” rating in a research report on Friday, May 1st. Needham & Company LLC boosted their price target on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, May 1st. Barclays reduced their price target on Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating for the company in a research report on Thursday, March 26th. Finally, Zacks Research upgraded Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 7th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Pacira BioSciences currently has an average rating of “Hold” and an average price target of $29.40.

Pacira BioSciences Stock Down 1.6%

PCRX opened at $22.99 on Friday. The stock’s fifty day moving average is $23.58 and its 200-day moving average is $23.27. The company has a market capitalization of $904.61 million, a PE ratio of 191.60 and a beta of 0.29. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.35 and a current ratio of 4.73. Pacira BioSciences, Inc. has a one year low of $18.80 and a one year high of $27.64.

Pacira BioSciences (NASDAQ:PCRX) last announced its earnings results on Thursday, April 30th. The company reported $0.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The company had revenue of $177.38 million for the quarter, compared to analyst estimates of $171.80 million. Pacira BioSciences had a return on equity of 10.24% and a net margin of 0.70%.The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period last year, the firm earned $0.65 earnings per share. On average, equities analysts predict that Pacira BioSciences, Inc. will post 1.91 EPS for the current fiscal year.

Insider Transactions at Pacira BioSciences

In other news, insider Jonathan Slonin sold 3,261 shares of the business’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total transaction of $74,416.02. Following the sale, the insider directly owned 223,640 shares of the company’s stock, valued at $5,103,464.80. The trade was a 1.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Shawn Cross sold 12,941 shares of the business’s stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $25.16, for a total value of $325,595.56. Following the sale, the chief financial officer directly owned 105,341 shares in the company, valued at $2,650,379.56. This trade represents a 10.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 34,376 shares of company stock valued at $846,312 over the last three months. Company insiders own 6.40% of the company’s stock.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.